Received Oct 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
never received the second dose; The patient developed Shingles; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix and did not receive 2nd dose of Shingrix. In AUG-2025, more than 2 years after receiving Shingrix, the patient experienced shingles (Verbatim: The patient developed Shingles ). The patient experienced incomplete course of vaccination (Verbatim: never received the second dose). The outcome of the shingles was unknown and the outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK Receipt Date: 03-OCT-2025 The patient received the first dose of Shingrix in 2018 and never received the second dose. The patient developed Shingles in the beginning of AUG 2025. The batch number was not provided, and we are unable to contact the reporter.